Literature DB >> 15480167

A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation.

Katarina Le Blanc1, Mats Remberger, Mehmet Uzunel, Jonas Mattsson, Lisbeth Barkholt, Olle Ringdén.   

Abstract

BACKGROUND: Nonmyeloablative (NM) conditioning and reduced-intensity conditioning (RIC) are increasingly used for allogeneic hematopoietic stem-cell transplantation. Such regimens have not been compared.
METHODS: The primary endpoint was graft-versus-host disease (GVHD). Secondary endpoints included transfusions, engraftment, and transplant-related mortality (TRM). NM conditioning (n=24) consisted of fludarabine and 2-Gy total-body irradiation followed by immunosuppression with cyclosporine A (CsA) combined with mycophenolate mofetil (MMF). The RIC (n=34) protocol consisted of fludarabine combined with busulfan or cyclophosphamide, antithymocyte globulin, and posttransplant immunosuppression CsA plus methotrexate. Diagnoses included hematologic malignancies and solid tumors. Donors were 34 human leukocyte antigen-identical siblings and 24 unrelated donors. Chimerism was analyzed by polymerase chain reaction of minisatellites.
RESULTS: Graft failure occurred in 6 of 24 in the NM group and in 1 of 34 in the RIC group, which was a significant difference (odds ratio [OR], 22.6; P=0.02). The NM group also had less leukopenia and required fewer erythrocyte and platelet transfusions than the RIC group. The time to and proportion of CD3, CD19, and CD45 donor chimerism were similar in both groups. The cumulative incidence of grades II to IV acute GVHD was higher in the NM group (59% vs. 12%; OR, 26.9; P<0.001), but we found no difference in the cumulative incidence of chronic GVHD (41% vs. 61%). TRM was 42% in the NM group and 20% in the RIC patients (relative hazard, 11.6; P=0.03).
CONCLUSIONS: NM conditioning with posttransplant immunosuppression using CsA and MMF resulted in less leukopenia and fewer transfusions, but resulted in more cases of graft failure, acute GVHD, and TRM than in RIC patients.

Entities:  

Mesh:

Year:  2004        PMID: 15480167     DOI: 10.1097/01.tp.0000129809.09718.7e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

1.  Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.

Authors:  Yoshihiro Inamoto; Taku Oba; Koichi Miyamura; Seitaro Terakura; Akane Tsujimura; Yachiyo Kuwatsuka; Masahiro Tokunaga; Masanobu Kasai; Makoto Murata; Tomoki Naoe; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Authors:  Stephanie B Tsai; Hongtao Liu; Tsiporah Shore; Yun Fan; Michael Bishop; Melissa M Cushing; Usama Gergis; Lucy Godley; Justin Kline; Richard A Larson; Guadalupe Martinez; Sebastian Mayer; Olatoyosi Odenike; Wendy Stock; Amittha Wickrema; Koen van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-19       Impact factor: 5.742

3.  Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.

Authors:  H Alchalby; D-R Yunus; T Zabelina; F Ayuk; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

Review 4.  Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions.

Authors:  A Tyndall; R Saccardi
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation.

Authors:  Allison R Butts; Victoria T Brown; Lauren D McBride; Javier Bolaños-Meade; Amy W Bryk
Journal:  J Oncol Pharm Pract       Date:  2015-03-22       Impact factor: 1.809

Review 6.  Graft failure after allogeneic hematopoietic cell transplantation.

Authors:  Jonas Mattsson; Olle Ringdén; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

7.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

Review 8.  Prophylaxis of acute GVHD: manipulate the graft or the environment?

Authors:  A John Barrett; Katarina Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

9.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.

Authors:  Zejing Wang; Mohamed L Sorror; Wendy Leisenring; Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb
Journal:  Br J Haematol       Date:  2010-01-11       Impact factor: 6.998

10.  Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure.

Authors:  Hong Xu; Yiming Huang; Paula M Chilton; Lala-Rukh Hussain; Michael K Tanner; Jun Yan; Suzanne T Ildstad
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.